The genetics and neuropathology of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.
Abstract
Here we review the genetic causes and risks for Alzheimer’s disease (AD). Early work identified mutations in three genes that cause AD: APP, PSEN1 and PSEN2. Although mutations in these genes are rare causes of AD, their discovery had a major impact on our understanding of molecular mechanisms of AD. Early work also revealed the ε4 allele of the APOE as a strong risk factor for AD. Subsequently, SORL1 also was identified as an AD risk gene. More recently, advances in our knowledge of the human genome, made possible by technological advances and methods to analyze genomic data, permit systematic identification of genes that contribute to AD risk. This work, so far accomplished through single nucleotide polymorphism arrays, has revealed nine new genes implicated in AD risk (ABCA7, BIN1, CD33, CD2AP, CLU, CR1, EPHA1, MS4A4E/MS4A6A, and PICALM). We review the relationship between these mutations and genetic variants and the neuropathologic features of AD and related disorders. Together, these discoveries point toward a new era in neurodegenerative disease research that impacts not only AD but also related illnesses that produce cognitive and behavioral deficits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 1×
“On a population level, people with an e4 allele have lower average onset age and those with an e2 allele have a higher average onset age for AD [21].”
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“Progress in AD genetics began with the identification of autosomal dominant mutations in APP [37].”
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 1×
“This partial sequence and additional sequence determined by others [107] were subsequently used by Kang et al.”
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 1×
“Subsequent work showed that polymorphisms within the APOE gene were strongly associated with AD [152].”
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487 · cited 2×
“One quantitative trait GWAS of lipid levels [161], e.”
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577 · cited 1×
“In the Volga German kindreds, the families that facilitated identification of PSEN2 mutations, onset ranges from the early 1940s to the 7th and 8th decade of life [91].”
Self-citation
Cited by
Brain-Gut-Microbiota Axis in Alzheimer’s Disease
Kowalski, K., & Mulak, A. (2019) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18087 · Cited by 826
“or aggregation propensity of Aβ is sufficient to cause AD, while Aβ aggregation is critical for the pathogenesis of the disease.(10) The majority of AD cases are its LOAD type, where different genes contribute to susceptibility for the disease.”
BackgroundThe case for rejecting the amyloid cascade hypothesis
Herrup, K. (2015) · Nature Neuroscience · doi:10.1038/nn.4017 · Cited by 768
Altered Ribostasis: RNA-Protein Granules in Degenerative Disorders
Ramaswami, M., Taylor, J. P., & Parker, R. (2013) · Cell · doi:10.1016/j.cell.2013.07.038 · Cited by 595
At the interface of sensory and motor dysfunctions and Alzheimer’s disease.
Albers, M. W., Gilmore, G. C., Kaye, J., Murphy, C., Wingfield, A., Bennett, D. A., Boxer, A. L., Buchman, A. S., Cruickshanks, K. J., Devanand, D. P., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.04.514 · Cited by 589
“Third, genome-wide association studies have now established multiple susceptibility genes for non-Mendelian forms of AD, many of which have proposed molecular effects on the production, aggregation, or clearance of Ab [11] and other AD-related molecules such as ApoE [12].”
BackgroundWang, M., Beckmann, N. D., Roussos, P., Wang, E., Zhou, X., Wang, Q., Ming, C., Neff, R., Ma, W., Fullard, J. F., et al. (2018) · Scientific Data · doi:10.1038/sdata.2018.185 · Cited by 502
Biology and Genetics of Prions Causing Neurodegeneration
Prusiner, S. B. (2013) · Annual Review of Genetics · doi:10.1146/annurev-genet-110711-155524 · Cited by 455
“FTD: frontotemporal dementia (PS1 and PS2) that encode the catalytic subunits of γ-secretase; these mutations result in elevated levels of wild-type Aβ peptide (Table 1) (55, 68, 163, 164, 175, 176).”
Corces, M. R., Shcherbina, A., Kundu, S., Gloudemans, M. J., Frésard, L., Granja, J. M., Louie, B. H., Eulalio, T., Shams, S., Bagdatli, S. T., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-00721-x · Cited by 358
Self-citationMutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors
Crotti, A., Benner, C., Kerman, B. E., Gosselin, D., Lagier-Tourenne, C., Zuccato, C., Cattaneo, E., Gage, F. H., Cleveland, D. W., & Glass, C. K. (2014) · Nature Neuroscience · doi:10.1038/nn.3668 · Cited by 333
Eph Receptors and Ephrins: Therapeutic Opportunities
Barquilla, A., & Pasquale, E. B. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140226 · Cited by 294
The choreography of neuroinflammation in Huntington's disease
Crotti, A., & Glass, C. K. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.04.007 · Cited by 276
“In contrast to PD and AD, which are complex multifactorial pathologies related to a spectrum of genetic mutations and environmental factors [3,4], HD or Huntington’s chorea, is a neurodegenerative disorder caused by a single mutation: a specific expansion of the PolyQ tract in the ubiquitously expressed HTT protein [6…”
BackgroundClearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
Zuroff, L., Daley, D., Black, K. L., & Koronyo-Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 275
Elevated Serum Pesticide Levels and Risk for Alzheimer Disease
Richardson, J. R., Roy, A., Shalat, S. L., von Stein, R. T., Hossain, M. M., Buckley, B., Gearing, M., Levey, A. I., & German, D. C. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.6030 · Cited by 263
Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias
Murray, M. E., Kouri, N., Lin, W.-L., Jack, C. R., Dickson, D. W., & Vemuri, P. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt231 · Cited by 236
“Readers are referred to recent reviews that cover the breadth of genetic forms of AD [17] and FTLD [18].”
BackgroundRossini, P. M., Di Iorio, R., Vecchio, F., Anfossi, M., Babiloni, C., Bozzali, M., Bruni, A. C., Cappa, S. F., Escudero, J., Fraga, F. J., et al. (2020) · Clinical Neurophysiology · doi:10.1016/j.clinph.2020.03.003 · Cited by 233
Unifying principles of bifunctional, proximity-inducing small molecules
Gerry, C. J., & Schreiber, S. L. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0469-1 · Cited by 199
Bridging integrator 1 (BIN1): form, function, and Alzheimer's disease
Tan, M.-S., Yu, J.-T., & Tan, L. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.06.004 · Cited by 189
The Ubiquitin-Proteasome System in Neurodegeneration
McKinnon, C., & Tabrizi, S. J. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5802 · Cited by 165
“NFTs are composed of aggregates of hyperpho-sphorylated tau, while the principal component of amyloid plaques is a 40-to 42-residue peptide called b -amyloid protein (A b 1–40 and A b 1–42 ) (161).”
APOE-ε2 and APOE-ε4 Correlate With Increased Amyloid Accumulation in Cerebral Vasculature
Nelson, P. T., Pious, N. M., Jicha, G. A., Wilcock, D. M., Fardo, D. W., Estus, S., & Rebeck, G. W. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31829a25b9 · Cited by 150
ABCA7 expression is associated with Alzheimer's disease polymorphism and disease status
Vasquez, J. B., Fardo, D. W., & Estus, S. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.09.058 · Cited by 101
“GWAS have identified genes in pathways that modulate AD risk, including genetic variants in ABCA7 (reviewed in [3, 36]).”
BackgroundWalker, D. G., Whetzel, A. M., Serrano, G., Sue, L. I., Beach, T. G., & Lue, L.-F. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.09.023 · Cited by 93
“Certain mutations in the amyloid precursor protein or presenilin result in the autosomal dominant transmission of AD (Bertram et al., 2010; Schellenberg and Montine, 2012).”
BackgroundScholtzova, H., Do, E., Dhakal, S., Sun, Y., Liu, S., Mehta, P. D., & Wisniewski, T. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1967-16.2016 · Cited by 82
“Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is characterized by parenchymal amyloid- (A ) plaque deposition, cerebral amyloid angiopathy (CAA), and neurofibrillary tangle formation (Schellenberg and Montine, 2012).”
BackgroundElias-Sonnenschein, L. S., Helisalmi, S., Natunen, T., Hall, A., Paajanen, T., Herukka, S.-K., Laitinen, M., Remes, A. M., Koivisto, A. M., Mattila, K. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059676 · Cited by 70
“Functions of the AlzGene variants in relation to AD have been previously described [9,14,15].”
BackgroundRoses, A., Sundseth, S., Saunders, A., Gottschalk, W., Burns, D., & Lutz, M. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.015 · Cited by 70
“TOMM400523 association with AD age of onset has received the same skeptical welcome that had been the case for APOE in the early 1990s [3,16].”
Tau-induced pathology in epilepsy and dementia: notions from patients and animal models.
Sánchez, M., García-Cabrero, A., Sánchez-Elexpuru, G., Burgos, D., & Serratosa, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041092 · Cited by 68
“These mutations give rise to early-onset forms of the disease [36,37] (Alzheimer Disease & Frontotemporal Dementia Mutation Database, Available online: http://www.”
BackgroundRevisiting rodent models: Octodon degus as Alzheimer’s disease model?
Steffen, J., Krohn, M., Paarmann, K., Schwitlick, C., Brüning, T., Marreiros, R., Müller-Schiffmann, A., Korth, C., Braun, K., & Pahnke, J. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0363-y · Cited by 62
“A small proportion of AD cases involve genetic variations which entail alterations in amount, ratio or amino acid sequence of Aβ [9].”
Li, X., Montine, K. S., Keene, C. D., & Montine, T. J. (2015) · The FASEB Journal · doi:10.1096/fj.14-262683 · Cited by 54
“Current genomewide association studies and the search for rare variants that increase risk for AD have linked several genes categorized as immune response genes (1, 2).”
BackgroundSelf-citationInduced pluripotent stem cells as a discovery tool for Alzheimer׳s disease
Sullivan, S. E., & Young-Pearse, T. L. (2017) · Brain Research · doi:10.1016/j.brainres.2015.10.005 · Cited by 50
Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer’s disease
Wirths, O., & Zampar, S. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1702972 · Cited by 44
Somatic Signature of Brain-Specific Single Nucleotide Variations in Sporadic Alzheimer's Disease
Parcerisas, A., Rubio, S. E., Muhaisen, A., Gómez-Ramos, A., Pujadas, L., Puiggros, M., Rossi, D., Ureña, J., Burgaya, F., Pascual, M., et al. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140891 · Cited by 44
Reelin proteolysis affects signaling related to normal synapse function and neurodegeneration
Lussier, A. L., Weeber, E. J., & Rebeck, G. W. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00075 · Cited by 31
Metadata
- Authors
- Schellenberg, G. D., & Montine, T. J.
- Venue
- Acta Neuropathologica
- Published
- 2012-05-23
- Volume
- 124
- Issue
- 3
- Pages
- 305-323
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W1967347174
- Cited by
- 242
- References
- 174
- FWCI
- 19.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.